SEMA4D and cancer: It is hypothesized that antibody neutralization of CD100 inhibits cancer progression by disrupting the CD100–PLXNB1 interaction in tumor tissues and enhancing recruitment of activated monocytes and lymphocytes into the tumor (9, 10, 30, 31).